KoBioLabs, Inc (KOSDAQ:348150)
South Korea
· Delayed Price · Currency is KRW 4,605.00
+30.00 (0.66%)
Last updated: Mar 25, 2025
KoBioLabs Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Operating Revenue | 68,359 | 33,138 | 11,606 | 2,893 | 4,591 | Upgrade
|
| Other Revenue | - | - | -0 | -0 | - | Upgrade
|
| Revenue | 68,359 | 33,138 | 11,606 | 2,893 | 4,591 | Upgrade
|
| Revenue Growth (YoY) | 106.29% | 185.53% | 301.12% | -36.98% | 696.41% | Upgrade
|
| Cost of Revenue | 21,565 | 9,429 | 3,627 | 995.01 | 1,956 | Upgrade
|
| Gross Profit | 46,794 | 23,709 | 7,979 | 1,898 | 2,636 | Upgrade
|
| Selling, General & Admin | 46,134 | 27,321 | 13,675 | 5,580 | 5,894 | Upgrade
|
| Research & Development | 6,905 | 14,262 | 14,198 | 12,496 | 8,882 | Upgrade
|
| Other Operating Expenses | 196 | 173.28 | 163.74 | 25.93 | 87.18 | Upgrade
|
| Operating Expenses | 53,699 | 42,167 | 28,270 | 18,236 | 14,981 | Upgrade
|
| Operating Income | -6,905 | -18,458 | -20,292 | -16,337 | -12,345 | Upgrade
|
| Interest Expense | -1,158 | -1,532 | -1,683 | -152.59 | -708.11 | Upgrade
|
| Interest & Investment Income | 2,408 | 3,253 | 2,135 | 499.93 | 402.93 | Upgrade
|
| Currency Exchange Gain (Loss) | 1,010 | 653.71 | 36.2 | 113.34 | 242.53 | Upgrade
|
| Other Non Operating Income (Expenses) | 144.16 | 1,384 | -3,223 | -498.84 | -42,665 | Upgrade
|
| EBT Excluding Unusual Items | -4,501 | -14,700 | -23,026 | -16,376 | -55,072 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 11.51 | 7.08 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -123.43 | - | -15.41 | 0.26 | - | Upgrade
|
| Other Unusual Items | 447.05 | 16.99 | - | - | - | Upgrade
|
| Pretax Income | -4,178 | -14,683 | -23,030 | -16,368 | -55,072 | Upgrade
|
| Income Tax Expense | 439.17 | 475.14 | 355.52 | -986.27 | - | Upgrade
|
| Earnings From Continuing Operations | -4,617 | -15,158 | -23,386 | -15,382 | -55,072 | Upgrade
|
| Minority Interest in Earnings | -681.1 | 1,305 | 1,464 | - | - | Upgrade
|
| Net Income | -5,298 | -13,853 | -21,921 | -15,382 | -55,072 | Upgrade
|
| Net Income to Common | -5,298 | -13,853 | -21,921 | -15,382 | -55,072 | Upgrade
|
| Shares Outstanding (Basic) | 19 | 19 | 17 | 16 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 19 | 19 | 17 | 16 | 11 | Upgrade
|
| Shares Change (YoY) | 3.65% | 10.26% | 4.68% | 49.69% | 51.75% | Upgrade
|
| EPS (Basic) | -276.00 | -748.00 | -1305.15 | -958.62 | -5137.55 | Upgrade
|
| EPS (Diluted) | -276.00 | -748.00 | -1305.15 | -959.00 | -5138.00 | Upgrade
|
| Free Cash Flow | -5,995 | -28,966 | -31,239 | -17,993 | -12,896 | Upgrade
|
| Free Cash Flow Per Share | -312.34 | -1564.04 | -1859.88 | -1121.36 | -1202.99 | Upgrade
|
| Gross Margin | 68.45% | 71.55% | 68.75% | 65.61% | 57.41% | Upgrade
|
| Operating Margin | -10.10% | -55.70% | -174.84% | -564.66% | -268.87% | Upgrade
|
| Profit Margin | -7.75% | -41.80% | -188.89% | -531.63% | -1199.45% | Upgrade
|
| Free Cash Flow Margin | -8.77% | -87.41% | -269.17% | -621.88% | -280.86% | Upgrade
|
| EBITDA | -4,327 | -16,943 | -19,383 | -16,105 | -12,135 | Upgrade
|
| EBITDA Margin | -6.33% | -51.13% | -167.02% | - | -264.30% | Upgrade
|
| D&A For EBITDA | 2,578 | 1,515 | 908.06 | 232.72 | 209.89 | Upgrade
|
| EBIT | -6,905 | -18,458 | -20,292 | -16,337 | -12,345 | Upgrade
|
| EBIT Margin | -10.10% | -55.70% | -174.84% | - | -268.87% | Upgrade
|
| Advertising Expenses | 14,172 | 7,806 | 3,478 | 717.8 | - | Upgrade
|
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.